FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - January 7, 2026 104 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology MOST POPULAR Trastuzumab Deruxtecan Demonstrates Durable Responses in Patients with Previously Treated HER2-mutated... September 27, 2023 POT1 Mutations Associated with Long Telomere Length Confer a Predisposition to... May 17, 2023 Volunteering with Pride: Brett’s award-winning involvement with Cancer Research UK June 15, 2023 What’s happened to cancer services during the COVID-19 pandemic? September 11, 2020 Load more HOT NEWS More Than 25 Additional Years Needed to Slow an Increasing Incidence... 2022 ASCO Annual Meeting Research Round Up: New Research in Head... No OS Benefit for Active Maintenance Treatment with Olaparib Relative to... Courageous children receive Star Awards in virtual celebration
